Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival

Human Pathology

Volumn 28, Issue 6, 1997, Pages 686-692

  Gansler, Ted S ^b   Hardman III, William ^b   Hunt, Dirk A ^b   Schaffel, Steven ^b   Hennigar, Randolph A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Fatty acid synthase; Lipid metabolism; Ovarian cancer; Prognostic markers

Indexed keywords

FATTY ACID SYNTHASE;

ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; COLORECTAL CANCER; ENZYME INDUCTION; FATTY ACID SYNTHESIS; HUMAN; HUMAN TISSUE; LIPID METABOLISM; MIXED MULLERIAN TUMOR; OVARY CARCINOMA; PROGNOSIS; PROSTATE CARCINOMA;

EID: 0031007392     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90177-5     Document Type: Article

References (30)

1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics, 1996. CA 65:5-27, 1996
2. Hollingsworth HC, Kohn EC, Steinberg SM, et al: Tumor angiogenesis in advanced stage ovarian carcinoma [see comments]. Am J Pathol 147:33-41, 1995
3. van Dam PA, Vergote IB, Lowe DG, et al: Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 47:914-919, 1994
4. Singleton TP, Perrone T, Oakley G, et al: Activation of c-erbB-2 and prognosis in ovarian carcinoma: Comparison with histologic type, grade, and stage. Cancer 73:1460-1466, 1994
5. Bellacosa A, de Feo D, Godwin AK, et al: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280-285, 1995
6. Fajac A, Benard J, Lhomme C, et al: c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: Evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer 64:146-151, 1995
7. van der Zee AG, Hollema H, Suurmeijer AJ, et al: Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13:70-78, 1995
8. Bosari S, Viale G, Radaelli U, et al: p53 accumulation in ovarian carcinomas and its prognostic implications. HUM PATHOL 24:1175-1179, 1993
9. Levesque MA, Katsaros D, Yu H, et al: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:1327-1338, 1995
10. Price FV, Chambers SK, Chambers JT, et al: Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am J Obstet Gynecol 168:520-527, 1993
11. Scambia G, Panici PB, Ferrandina G, et al: Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 30A:935-940, 1994
12. Kühn W, Pache L, Schmalfeldt B, et al: Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55:401-409, 1994
13. Satoh T, Nishida M, Miyazaki Y, et al: An immunohistological study on expression of glutathione S-transferase pi (form) in human ovarian carcinoma. Acta Obstet Gynaecol Japonica 47:931-938, 1995
14. Alberts WA, Greenspan MD: Animal and bacterial fatty acid synthetase: Structure, function and regulation, in Neuberger A, Van Deenen LLM (eds): New Comprehensive Biochemistry, vol 7. New York, NY, Elsevier, 1984, pp 29-58
15. Wakil SJ: Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28:4523-4530, 1989
16. Goodridge AG: Fatty acid synthesis in eucaryotes, in Vance DE, Vance J (eds): New Comprehensive Biochemistry, vol 20. New York, Elsevier, 1991, pp 111-139
17. Smith S: The animal fatty acid synthase: One gene, one polypeptide, seven enzymes. FASEB J 8:1248-1259, 1994
18. Reston MS, Kern SE, Vogelstein B, et al: Expression of OA-519 (Haptoglobin-related protein epitopes) in colorectal cancers: Comparison with molecular genetic alterations and metastasis. Lab Invest 66:47A, 1992
19. Shurbaji MS, Kuhajda FP, Pasternack GP, et al: Expression of oncoantigen 519 (OA-519) in prostate cancer is a potential prognostic indicator. Am J Clin Pathol 97:686-691, 1992
20. Epstein J, Carmichael M, Partin A: OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology 45:81-86, 1995
21. Jensen V, Ladekarl M, Holm-Nielsen P, et al: The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-I in node-negative breast cancer. J Pathol 176:343-352, 1995
22. Alo PL, Visca P, Marci A, et al: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77:474-482, 1996
23. Martin AW, Corrigan C, Kuhns G, et al: Fatty acid synthase (OA-519) detection and survival probability in breast cancer. Cancer Res (in press)
24. Thompson BJ, Stern A, Smith S: Purification and properties of fatty acid synthetase from a human breast cell line. Biochem Biophys Acta 662:125-130, 1981
25. Kuhajda FP, Jenner K, Wood FD, et al: Fatty acid synthase: A potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 91:6379-6383, 1994
26. Heine HS, Matsuzaki M, Wood FD, et al: Increased rates of fatty acid synthesis in breast cancer and identification of unique products. Cancer Res 36:505, 1995
27. Weiss L, Hoffman GE, Schreiber R, et al: Fatty acid biosynthesis in man, a pathway of minor importance: Purification, optimal assay conditions, and organ distribution of fatty acid synthase. Biol Chem Hoppes-Seyer 367:905-912, 1986
28. Czernobilsky B: Common epithelial tumors of the ovary, in Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract (ed 3). New York, NY, Springer-Verlag, 1987, p 562
29. Pizer ES, Wood FD, Pasternack GR, et al: Fatty acid synthase (FAS): A target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res 56:745-751, 1996
30. Pizer ES, Wood FD, Heine SH, et al: Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56:1189-1193, 1996